The value of dual time point 18F-FDG PET imaging for the differentiation between malignant and benign lesions

Clinical Radiology

Volumn 63, Issue 7, 2008, Pages 756-764

  Lan, X L ^a   Zhang, Y X ^a   Wu, Z J ^a   Jia, Q ^a   Wei, H ^a   Gao, Z R ^a  

^a Union Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL TRIAL; COLON CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; FEMALE; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LUNG CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM TUMOR; NASOPHARYNX CANCER; OVARY CANCER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECURRENT CANCER; STOMACH CARCINOMA; THYROID CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 46549084511     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2008.01.003     Document Type: Article

References (22)

1. Rohren E.M., Turking T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 (2004) 305-332
2. Jarritt P.H., Carson K.J., Hounsell A.R., et al. The role of PET/CT scanning in radiotherapy planning. Br J Radiol 79 (2006) S27-S35
3. Rigo P., Paulus P., Kaschten B.J., et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23 (1996) 1641-1674
4. Endo K., Oriuchi N., Higuchi T., et al. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 11 (2006) 286-296
5. Chang J.M., Lee H.J., Goo J.M., et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol 7 (2006) 57-69
6. Zhuang H., Pourdehnad M., Lambright E.S., et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42 (2001) 1412-1417
7. Liang Y.-C., Tang A.-W., and Xu H. Diagnostic value of (18)F-FDG PET delayed imaging for patients with primary lung cancer. Chin J Nucl Med 24 (2004) 27-29 [in Chinese]
8. Kumar R., Loving V.A., Chauhan A., et al. Potential of dual-time-point imaging to improve breast cancer diagnosis with 18F-FDG PET. J Nucl Med 46 (2005) 1819-1824
9. Matthies A., Hickeson M., Cuchiara A., et al. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43 (2002) 871-875
10. Hustinx R., Smith R.J., Benard F., et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26 (1999) 1345-1348
11. 18F-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun 4 (2003) 1129-1137
12. van Waarde A., Jager P.L., Ishiwata K., et al. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 47 (2006) 150-154
13. Takamochi K., Yoshida J., Murakami K., et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 47 (2005) 235-242
14. Kamel E.M., McKee T.A., Calcagni M.L., et al. Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies. Eur J Nucl Med Mol Imaging 32 (2005) 641-646
15. 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 47 (2006) 256-261
16. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 48 (2007) 35-45
17. Hashimoto Y., Tsujikawa T., Kondo C., et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 47 (2006) 426-431
18. Hubner K.F., Buonocore E., Gould H.R., et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Chin J Nucl Med 21 (1996) 941-949
19. Kruger S., Buck A.K., Blumstein N.M., et al. Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours. J Intern Med 260 (2006) 545-550
20. Yamada S., Kubota K., Kubota R., et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 36 (1995) 1301-1306
21. 18FDG uptake in soft tissue masses. Eur J Nucl Med 26 (1999) 22-30
22. Hamberg L.M., Hunter G.J., Alpert N.M., et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med 35 (1994) 1308-1312